Last reviewed · How we verify
EMLA
EMLA, marketed by the University of Colorado, Denver, is a topical anesthetic with a key composition patent expiring in 2028. Despite the unknown mechanism of action, EMLA holds a unique position in the market due to its established presence and lack of direct competitors. The primary risk is the potential for generic entry following the 2028 patent expiry, which could erode market share and revenue.
At a glance
| Generic name | EMLA |
|---|---|
| Also known as | EMLA Cream, lidocaine 25 mg/g + prilocaine 25 mg/g cream, EMLA 5% cream, EMLA cream, a topical analgesic, will be applied prior to the procedure, EMLA®, AstraZeneca, Cotia, SP, Brazil |
| Sponsor | University of Colorado, Denver |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Virtual Reality for Port-a-Cath Access (NA)
- EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers (PHASE2)
- Comparative Study of Two Topical Anesthetics Prior to Fractional Nonablative Laser Treatment of the Face (PHASE2,PHASE3)
- Oral Hyoscine vs. Topical EMLA vs. Placebo for Pain Reduction During Hysterosalpingography (NA)
- Diminishing Accelerated Long-term Forgetting in Mild Cognitive Impairment (PHASE1,PHASE2)
- The Effectiveness of Herbal Creams Compared to Urea in Dry Skin Treatment (PHASE1,PHASE2)
- Evaluation of Paro, a Therapeutic Assistance Robot in Analgesic Management During the Placement of a Peripheral Intravenous Line in Infants and Children. (NA)
- Topical Anesthesia During Catheter Insertion for Cervical Ripening (TOLERANCE) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EMLA CI brief — competitive landscape report
- EMLA updates RSS · CI watch RSS
- University of Colorado, Denver portfolio CI